Using a combination of deep analysis of liver genetics and precision RNA design, Ochre Bio is developing breakthrough RNA therapies for chronic liver diseases like hepatitis, cirrhosis and liver cancer. On this episode of the AWS Health Innovation Podcast, host Dr. Terence Tan speaks with Ochre Bio Co-Founder & CSO Quin Wills about the company's unique approach to treating liver disease.

We cover:

Transdisciplinary Science

Ochre Bio believes combining deep expertise across genetics, computer science, and math enables the company to accelerate liver disease research.

RNA Therapies

Ochre Bio selected RNA therapies as the modality for targeting liver diseases based on RNA's potential to maximize success.

Human-Relevant Platform

Ochre Bio uses human cells, tissues and organs to validate findings without relying solely on animal models.

Aiming Big Picture

Unlike biotechs focused on one part of the value chain, Ochre Bio wants to improve prediction, validation and clinical trials holistically.

COVID Challenges

COVID severely impacted Ochre Bio's access to human livers, requiring quick iteration as organ transplants reopened post-pandemic.

Partnership Plans

Ochre Bio will soon announce partnerships with two major pharmas to generate large, high-quality data sets for discovering new liver disease targets.

Pushing Boundaries

Over the next 3 years, Ochre Bio aims to expand the boundaries of their platform's capabilities in discovery, validation and translation.

Tackling Tissue Remodeling

The team recently set goals to study liver metabolism, cell death and tackle major tissue remodeling and scarring underlying diseases like cirrhosis.

Irrational AI Hype

Quin believes there is irrational investor excitement that AI will effectively solve many problems, when quality data remains extremely expensive.

Accelerating Learning Cycles

To get better AI predictions, we must close the 10-15 year learning cycle in biopharma with better data and feedback loops.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.